These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

682 related items for PubMed ID: 10737537

  • 1. A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters.
    Schwaab T, Heaney JA, Schned AR, Harris RD, Cole BF, Noelle RJ, Phillips DM, Stempkowski L, Ernstoff MS.
    J Urol; 2000 Apr; 163(4):1322-7. PubMed ID: 10737537
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients.
    Schwaab T, Schwarzer A, Wolf B, Crocenzi TS, Seigne JD, Crosby NA, Cole BF, Fisher JL, Uhlenhake JC, Mellinger D, Foster C, Szczepiorkowski ZM, Webber SM, Schned AR, Harris RD, Barth RJ, Heaney JA, Noelle RJ, Ernstoff MS.
    Clin Cancer Res; 2009 Aug 01; 15(15):4986-92. PubMed ID: 19622576
    [Abstract] [Full Text] [Related]

  • 7. Cytotoxic in vitro function in patients with metastatic renal cell carcinoma before and after alpha-2b-interferon therapy. Effects of activation with recombinant interleukin-2.
    Feruglio C, Zambello R, Trentin L, Bulian P, Franceschi T, Cetto GL, Semenzato G.
    Cancer; 1992 May 15; 69(10):2525-31. PubMed ID: 1568175
    [Abstract] [Full Text] [Related]

  • 8. Use of cryopreserved lymphocytes for assessment of the immunological effects of interferon therapy in renal cell carcinoma patients.
    Sobota V, Bubeník J, Indrová M, Vlk V, Jakoubková J.
    J Immunol Methods; 1997 Apr 11; 203(1):1-10. PubMed ID: 9134025
    [Abstract] [Full Text] [Related]

  • 9. Characterization of tumor-infiltrating lymphocyte subsets from human renal cell carcinoma: specific reactivity defined by cytotoxicity, interferon-gamma secretion, and proliferation.
    Finke JH, Rayman P, Hart L, Alexander JP, Edinger MG, Tubbs RR, Klein E, Tuason L, Bukowski RM.
    J Immunother Emphasis Tumor Immunol; 1994 Feb 11; 15(2):91-104. PubMed ID: 7907918
    [Abstract] [Full Text] [Related]

  • 10. Human renal carcinoma line transfected with interleukin-2 and/or interferon alpha gene(s): implications for live cancer vaccines.
    Belldegrun A, Tso CL, Sakata T, Duckett T, Brunda MJ, Barsky SH, Chai J, Kaboo R, Lavey RS, McBride WH.
    J Natl Cancer Inst; 1993 Feb 03; 85(3):207-16. PubMed ID: 8423625
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma.
    Viey E, Fromont G, Escudier B, Morel Y, Da Rocha S, Chouaib S, Caignard A.
    J Immunol; 2005 Feb 01; 174(3):1338-47. PubMed ID: 15661891
    [Abstract] [Full Text] [Related]

  • 15. Patient-derived renal cell carcinoma cells fused with allogeneic dendritic cells elicit anti-tumor activity: in vitro results and clinical responses.
    Zhou J, Weng D, Zhou F, Pan K, Song H, Wang Q, Wang H, Wang H, Li Y, Huang L, Zhang H, Huang W, Xia J.
    Cancer Immunol Immunother; 2009 Oct 01; 58(10):1587-97. PubMed ID: 19221746
    [Abstract] [Full Text] [Related]

  • 16. Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial.
    Baek S, Kim CS, Kim SB, Kim YM, Kwon SW, Kim Y, Kim H, Lee H.
    J Transl Med; 2011 Oct 20; 9():178. PubMed ID: 22013914
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.
    Chang AE, Aruga A, Cameron MJ, Sondak VK, Normolle DP, Fox BA, Shu S.
    J Clin Oncol; 1997 Feb 20; 15(2):796-807. PubMed ID: 9053507
    [Abstract] [Full Text] [Related]

  • 19. Correlation of clinical and immunological parameters of metastatic renal cell carcinoma patients undergoing therapy with interleukin 2, interferon-alpha and retinoic acid.
    Elsässer-Beile U, Kölble N, Grussenmeyer T, Wetterauer U, Schultze-Seemann W.
    Anticancer Res; 1998 Feb 20; 18(3B):1883-90. PubMed ID: 9677439
    [Abstract] [Full Text] [Related]

  • 20. The prognostic significance of immune changes in patients with renal cell carcinoma treated with interferon alfa-2b.
    Kosmidis PA, Baxevanis CN, Tsavaris N, Papanastasiou M, Anastasopoulos E, Bacoyiannis C, Mylonakis N, Karvounis N, Bafaloukos D, Karabelis A.
    J Clin Oncol; 1992 Jul 20; 10(7):1153-7. PubMed ID: 1535102
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.